• Mehrzad Mirzania, Ardeshir Ghavamzadeh, Iraj Asvadi Kermani, Farzaneh Ashrafi, Abolghasem Allahyari, Nematollah Rostami, Seyed Mohsen Razavi, Mani Ramzi, and Gholamreza Nemanipour.
• Hematology and Medical Oncology Department, Cancer Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran. mirzania_m@yahoo.com.
• Arch Iran Med. 2015 Nov 1; 18 (11): 799-805.

AbstractSystemic therapy is one of the cornerstones of cancer treatment. In 1972, following representations by American Society of Clinical Oncology (ASCO), the American Board of Internal Medicine (ABIM) recognized medical oncology as a new subspecialty of internal medicine. Subspecialty of Hematology and Medical Oncology was emerged in Iran in 1983. In the past, modern medical treatments and education were started in Dar Al-fonun school and then in Tehran University; now six universities in Iran are training in Subspecialty of Hematology and Medical Oncology. There are also ten active hematopoietic stem cell transplantation centers, thirty-one provincial medical schools use their specialized services. Future goals for Hematology and Medical Oncology in Iran include expansion and reinforcement of multidisciplinary teams across the country, early detection and prevention of cancer, providing educational program and conducting cancer researches. To achieve these goals, it is necessary to establish Cancer Hospitals in each province that link together through a network.

16 keywords...

hide…